

# Christian Funck-Brentano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7375271/publications.pdf>

Version: 2024-02-01

265  
papers

101,197  
citations

9264

74  
h-index

507

268  
g-index

290  
all docs

290  
docs citations

290  
times ranked

64528  
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	2.2	5,681
2	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	2.2	5,233
3	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	2.2	5,034
4	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.5	4,778
5	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.2	4,537
6	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	2.2	4,210
7	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	2.2	3,915
8	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496.	2.2	3,465
9	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	2.2	3,144
10	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009, 30, 2493-2537.	2.2	3,108
11	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
12	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
13	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
14	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	2.2	2,649
15	Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.	2.2	2,645
16	Third universal definition of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012, 9, 620-633.	18.7	2,615
17	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	2.8	2,558
18	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	2.2	2,447

#	ARTICLE	IF	CITATIONS
19	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	1.7	2,319
20	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	7.1	2,307
21	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	2.2	2,128
22	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	7.1	1,893
23	Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2009, 30, 2369-2413.	2.2	1,822
24	Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2009, 30, 2631-2671.	2.2	1,784
25	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	2.2	1,758
26	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 3147-3197.	2.2	1,694
27	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	2.2	1,617
28	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	2.2	1,394
29	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	1.7	1,360
30	Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44.	1.4	1,313
31	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. <i>European Heart Journal</i> , 2014, 35, 2383-2431.	2.2	1,253
32	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 0 BT /Overlock 10 T</i>		
33	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet</i> , 2009, 373, 309-317.	13.7	864
34	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	2.2	735
35	2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Heart Journal</i> , 2010, 31, 2677-2687.	2.2	427
36	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	1.4	402

#	ARTICLE	IF	CITATIONS
37	Rate-corrected QT interval: Techniques and limitations. American Journal of Cardiology, 1993, 72, B17-B22.	1.6	359
38	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.8BT /Overb 10 T		
39	Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005, 106, 135-140.	1.4	335
40	2014 ESC/ESA Guidelines on non-cardiac surgery. European Journal of Anaesthesiology, 2014, 31, 517-573.	1.7	335
41	2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536.	1.7	297
42	2007 ESHâ€ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	1.5	292
43	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137.	1.7	263
44	Sex Differences in the Prognosis of Congestive Heart Failure. Circulation, 2001, 103, 375-380.	1.6	256
45	Prolongation of QTc Interval after Postoperative Nausea and Vomiting Treatment by Droperidol or Ondansetron. Anesthesiology, 2005, 102, 1094-1100.	2.5	243
46	Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. European Heart Journal, 1993, 14, 30-35.	2.2	188
47	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD â€ Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	2.0	173
48	Cardiovascular Toxicities AssociatedâWith Ibrutinib. Journal of the American College of Cardiology, 2019, 74, 1667-1678.	2.8	169
49	2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.	7.1	152
50	Digoxin pharmacokinetics and MDR1 genetic polymorphisms. European Journal of Clinical Pharmacology, 2003, 58, 809-812.	1.9	149
51	The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone. New England Journal of Medicine, 1990, 322, 1764-1768.	27.0	144
52	Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clinical Pharmacology and Therapeutics, 2000, 68, 658-666.	4.7	143
53	Propafenone. New England Journal of Medicine, 1990, 322, 518-525.	27.0	136
54	Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers*. Clinical Pharmacology and Therapeutics, 1998, 64, 192-203.	4.7	136

#	ARTICLE	IF	CITATIONS
55	CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. <i>Pharmacogenetics and Genomics</i> , 1993, 3, 197-204.	5.7	132
56	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. <i>Rheumatology</i> , 2007, 46, 808-810.	1.9	124
57	Stereoselective disposition and pharmacologic activity of propafenone enantiomers.. <i>Circulation</i> , 1989, 79, 1068-1076.	1.6	115
58	Can We Override Clopidogrel Resistance?. <i>Circulation</i> , 2009, 119, 2854-2857.	1.6	115
59	Droperidol and Ondansetron-induced QT Interval Prolongation. <i>Anesthesiology</i> , 2008, 109, 206-212.	2.5	114
60	Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 432-437.	4.7	112
61	Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 273-283.	3.8	111
62	Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). <i>European Heart Journal</i> , 2003, 24, 552-559.	2.2	109
63	Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. <i>Biochemical Pharmacology</i> , 1983, 32, 1063-1068.	4.4	108
64	Drug interactions and hepatitis produced by some macrolide antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 1985, 16, 181-194.	3.0	108
65	Cardiovascular Safety of Salmeterol in COPDa. <i>Chest</i> , 2003, 123, 1817-1824.	0.8	105
66	Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. , 2018, 189, 89-103.		101
67	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. <i>European Heart Journal</i> , 2011, 32, 41-50.	2.2	99
68	Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 391-402.	4.7	93
69	Uses of pharmacovigilance databases: An overview. <i>Therapie</i> , 2020, 75, 591-598.	1.0	92
70	Effects of Testosterone on Ventricular Repolarization in Hypogonadic Men. <i>American Journal of Cardiology</i> , 2009, 103, 887-890.	1.6	90
71	Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin. <i>Circulation</i> , 2020, 142, 303-305.	1.6	89
72	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010, 62, 2047-2054.	6.7	85

#	ARTICLE	IF	CITATIONS
73	QT Interval Measurement. <i>Anesthesiology</i> , 2006, 104, 255-260.	2.5	83
74	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. <i>ELife</i> , 2017, 6, .	6.0	82
75	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq1 1 0,784314 rgBT /Ov</i> Prevention & Rehabilitation (FACPR). [ <i>Eur Heart J</i> 2012;33:1635-1701. doi: 10.1093/eurhearti/ehs092]. <i>European Heart Journal</i> 2012, 33, 2126-2126.	2.2	79
76	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. <i>Drug Safety</i> , 2019, 42, 813-825.	3.2	78
77	Effect of grapefruit juice on digoxin pharmacokinetics in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 311-316.	4.7	77
78	Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 51-60.	4.7	75
79	Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 256-269.	4.7	74
80	Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans.. <i>Circulation</i> , 1991, 83, 536-545.	1.6	71
81	Influence of steroid hormones on ventricular repolarization. , 2016, 167, 38-47.		71
82	Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 373-376.	1.9	68
83	Androgenic Effects on Ventricular Repolarization. <i>Circulation</i> , 2019, 140, 1070-1080.	1.6	67
84	Geneticallyâ€determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 435-444.	2.4	66
85	Influence of Dofetilide on QT-Interval Duration and Dispersion at Various Heart Rates During Exercise in Humans. <i>Circulation</i> , 1996, 94, 1592-1599.	1.6	65
86	Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 533-542.	4.7	61
87	Is diclofenac a valuable CYP2C9 probe in humans?. <i>European Journal of Clinical Pharmacology</i> , 2001, 56, 793-797.	1.9	60
88	3-Hydroxybenzo[a]pyrene in the urine of smokers and non-smokers. <i>Toxicology Letters</i> , 2006, 162, 181-185.	0.8	57
89	Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 679-684.	4.7	57
90	Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 511-519.	2.4	57

#	ARTICLE	IF	CITATIONS
91	Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. <i>Circulation</i> , 2018, 138, 110-113.	1.6	57
92	Influence of endogenous oestrogens on QT interval duration. <i>European Heart Journal</i> , 2003, 24, 1663-1667.	2.2	52
93	Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 514-523.	4.7	51
94	Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 384-393.	4.7	50
95	Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 619-627.	4.7	49
96	Pharmacogenetics of acenocoumarol pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 403-414.	4.7	49
97	<i>In Vitro</i> Cardiovascular Effects of Dihydroartemisin-Piperaquine Combination Compared with Other Antimalarials. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3261-3270.	3.2	49
98	Pharmacokinetics and Platelet Antiaggregating Effects of Beraprost, an Oral Stable Prostacyclin Analogue, in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 711-716.	1.9	48
99	Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 499-503.	2.4	47
100	Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 601-604.	2.4	47
101	Effect of interferon $\pm$ ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 488-495.	4.7	47
102	Genetic and environmental risk factors for oral anticoagulant overdose. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 739-745.	1.9	47
103	QT interval prolongation after oxytocin bolus during surgical induced abortion. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 359-364.	4.7	47
104	Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 821-829.	1.9	47
105	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. <i>Annals of Oncology</i> , 2015, 26, 1470-1475.	1.2	46
106	Complex Influence of Gonadotropins and Sex Steroid Hormones on QT Interval Duration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2776-2784.	3.6	46
107	Hepatotoxicity of Trichloroethylene-Carbon Tetrachloride Mixtures in Rats. <i>Gastroenterology</i> , 1982, 83, 761-772.	1.3	44
108	Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. <i>Lung Cancer</i> , 2006, 54, 11-18.	2.0	44

#	ARTICLE	IF	CITATIONS
109	Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. <i>Nature Communications</i> , 2022, 13, 25.	12.8	44
110	Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 76-82.	2.4	42
111	Cardiac arrhythmia considerations of hormone cancer therapies. <i>Cardiovascular Research</i> , 2019, 115, 878-894.	3.8	42
112	Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 312-320.	3.0	42
113	Regulation of renal cytochrome P-450. <i>Biochemical Pharmacology</i> , 1985, 34, 311-320.	4.4	40
114	Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects*1. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 242-252.	4.7	40
115	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	2.2	40
116	Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. <i>European Heart Journal</i> , 2021, 42, 3915-3928.	2.2	38
117	Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. <i>Heart</i> , 2018, 104, 1859-1863.	2.9	37
118	Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 417-426.	4.7	36
119	Postoperative Analgesia and Recovery Course After Major Colorectal Surgery in Elderly Patients. <i>Regional Anesthesia and Pain Medicine</i> , 2006, 31, 531-538.	2.3	36
120	Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19 genotyped healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 610-613.	3.8	36
121	Concentration/response relations for the multiple antiarrhythmic actions of sotalol. <i>American Journal of Cardiology</i> , 1990, 65, 22-27.	1.6	35
122	Influence of liver cirrhosis on sertraline pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 394-397.	2.4	35
123	Reduced costs with bisoprolol treatment for heart failure; an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). <i>European Heart Journal</i> , 2001, 22, 1021-1031.	2.2	35
124	Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 397-402.	4.7	34
125	Steady-State versus Non-Steady-State QT-RR Relationships in 24-hour Holter Recordings. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 293-302.	1.2	33
126	Pharmacology and mechanisms of action of new oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 10-20.	1.9	33

#	ARTICLE	IF	CITATIONS
127	Dynamic analysis of dofetilide-induced changes in ventricular repolarization*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 312-321.	4.7	32
128	Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 100, 230-235.	2.8	32
129	Use of heterologously expressed human cytochrome P4501A2 to predict tacrine-fluvoxamine drug interaction in man. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 101-108.	5.7	31
130	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 938.e1-938.e59.	1.2	31
131	Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women. <i>JAMA Cardiology</i> , 2018, 3, 877.	6.1	30
132	Overview of the clinical pharmacology of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1988, 61, A61-A69.	1.6	28
133	The pharmacokinetics of perindopril in patients with liver cirrhosis.. <i>British Journal of Clinical Pharmacology</i> , 1992, 33, 326-328.	2.4	28
134	Corrected QT interval in anti-SSA-positive adults with connective tissue disease: Comment on the article by Lazerini et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 676-677.	6.7	28
135	Protective effect of 16,16-dimethyl prostaglandin E2 on the hepatotoxicity of bromobenzene in mice. <i>Biochemical Pharmacology</i> , 1984, 33, 89-96.	4.4	27
136	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 9-21.	1.6	27
137	Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome. <i>European Heart Journal</i> , 2021, 42, 3948-3961.	2.2	27
138	Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 507-512.	4.7	26
139	Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 583-592.	4.7	26
140	Postoperative Analgesia and Recovery Course After Major Colorectal Surgery in Elderly Patients: A Randomized Comparison Between Intrathecal Morphine and Intravenous PCA Morphine. <i>Regional Anesthesia and Pain Medicine</i> , 2006, 31, 531-538.	2.3	26
141	Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. <i>European Journal of Heart Failure</i> , 2011, 13, 765-772.	7.1	26
142	Influence of amiodarone on genetically determined drug metabolism in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 259-266.	4.7	25
143	Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 582-588.	4.7	25
144	Repeatability of Spectral Components of Short-Term Blood Pressure and Heart Rate Variability during Acute Sympathetic Activation in Healthy Young Male Subjects. <i>Clinical Science</i> , 1997, 93, 21-28.	4.3	24

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: Comparison with the standard form and influence of the CYP2D6 polymorphism*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 112-122.	4.7	24
146	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. <i>American Heart Journal</i> , 2017, 183, 91-101.	2.7	24
147	Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta-Analysis, and Meta-Regression to Identify Modifying Factors. <i>Journal of the American Heart Association</i> , 2019, 8, e013267.	3.7	24
148	Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1670-1682.	3.8	24
149	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. <i>Pharmaceuticals</i> , 2020, 13, 325.	3.8	23
150	Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 109-115.	2.4	22
151	Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 453-456.	2.4	22
152	Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. <i>Fundamental and Clinical Pharmacology</i> , 2000, 14, 519-525.	1.9	22
153	Influence of hormones on the immunotolerogenic molecule HLA-G: a cross-sectional study in patients with congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , 2019, 181, 481-488.	3.7	22
154	Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. <i>American Journal of Cardiology</i> , 1990, 66, 812-817.	1.6	19
155	A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 49-52.	2.4	19
156	Effects of cigarette smoking on short-term variability of blood pressure in smoking and non smoking healthy volunteers. <i>Fundamental and Clinical Pharmacology</i> , 1999, 13, 501-507.	1.9	19
157	Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 661-671.	1.6	19
158	Determination of Colistin and Colistimethate Levels in Human Plasma and Urine by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 796-803.	2.0	19
159	Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 531-538.	2.4	18
160	Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. <i>Fundamental and Clinical Pharmacology</i> , 1999, 13, 232-236.	1.9	18
161	Droperidol and ondansetron in vitro electrophysiological drug interaction study. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 719-726.	1.9	18
162	Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 699-712.	1.6	18

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetic and Pharmacodynamic Interaction of N-Acetyl Procainamide and Procainamide in Humans. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 14, 364-373.	1.9	17
164	d-Sotalol reduces heart rate in vivo through a $\beta_2$ -adrenergic receptor-independent mechanism. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 436-442.	4.7	17
165	Beta-blockade in CHF: from contraindication to indication. <i>Country Review Ukraine</i> , 2006, 8, C19-C27.	0.8	17
166	Drug-induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2540-2546.	2.4	17
167	Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103342.	4.4	17
168	Rate dependence of ventricular extrasystoles: computer identification and quantitative analysis. <i>Cardiovascular Research</i> , 1988, 22, 101-107.	3.8	16
169	Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 403-409.	2.4	15
170	Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. <i>Cardiovascular Therapeutics</i> , 2011, 29, 89-98.	2.5	15
171	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiología</i> , 2014, 67, 136.e1-136.e56.	1.2	15
172	Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 183, 113137.	2.8	15
173	Response to the editorial "COVID-19 in patients with cardiovascular diseases". <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 367-368.	1.6	15
174	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 197, 113968.	2.8	15
175	Rate dependence of class III actions in the heart. <i>Fundamental and Clinical Pharmacology</i> , 1993, 7, 51-59.	1.9	14
176	Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 257-263.	4.7	14
177	Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). <i>American Heart Journal</i> , 2001, 142, 989-997.	2.7	14
178	Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 122-129.	4.7	14
179	Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. <i>Revista Espanola De Cardiología</i> , 2013, 66, 54.e1-54.e24.	1.2	14
180	Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies. <i>Scientific Reports</i> , 2018, 8, 1681.	3.3	14

#	ARTICLE	IF	CITATIONS
181	Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. Therapeutic Drug Monitoring, 2019, 41, 476-482.	2.0	14
182	The Role of the Critical Event Committee in a Major Cardiovascular Outcome Study. Blood Pressure, 2002, 11, 339-344.	1.5	13
183	Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 125-138.	1.6	13
184	Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, 2017, 119, 75-93.	4.4	13
185	Complex Association of Sex Hormones on Left Ventricular Systolic Function: Insight into Sexual Dimorphism. Journal of the American Society of Echocardiography, 2018, 31, 231-240.e1.	2.8	13
186	Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Scientific Reports, 2019, 9, 883.	3.3	13
187	GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPolarization, the GENEREPOL study: Lack of common variants with large effect sizes. PLoS ONE, 2017, 12, e0181875.	2.5	13
188	Droperidol-induced Proarrhythmia. Anesthesiology, 2007, 107, 524-526.	2.5	12
189	Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation. Scientific Reports, 2019, 9, 777.	3.3	12
190	HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American Heart Association, 2020, 9, e017578.	3.7	12
191	Circulating Receptor Activator of Nuclear Factor $\kappa$ B Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 140.	6.8	12
192	Randomized study of the effect of gadopiclesol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects. British Journal of Clinical Pharmacology, 2020, 86, 2174-2181.	2.4	12
193	Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus. Pharmaceuticals, 2021, 14, 273.	3.8	12
194	Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clinical Pharmacology and Therapeutics, 1991, 49, 488-496.	4.7	11
195	Glutathione S-transferase ?? genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics and Genomics, 1997, 7, 251-253.	5.7	11
196	Open letter on access to the BIA 10-2474 clinical trial data. Lancet, The, 2017, 389, 156.	13.7	11
197	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Critical Reviews in Oncology/Hematology, 2019, 141, 112-124.	4.4	11
198	Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1800-1810.	2.3	11

#	ARTICLE	IF	CITATIONS
199	Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 120-127.	2.4	10
200	Fast, accurate and easy-to-teach QT interval assessment: The triplicate concatenation method. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 475-481.	1.6	10
201	Rapid Development of Nitrate Tolerance in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24, 266-273.	1.9	9
202	Effects of HIV Protease Inhibitors on Cardiac Conduction Velocity in Unselected HIV-Infected Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 442-448.	4.7	9
203	Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?. <i>European Journal of Cancer</i> , 2020, 136, 1-3.	2.8	9
204	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes. <i>PLoS ONE</i> , 2020, 15, e0229145.	2.5	9
205	Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man.. <i>British Journal of Clinical Pharmacology</i> , 1987, 24, 559-560.	2.4	8
206	Clinical evaluation of pain during subcutaneous injections of low molecular weight heparins in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 395-397.	2.4	8
207	Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): A study of the interactions between $\beta$ -blocker therapy and occurrence of critical events using analysis of competitive risks. <i>American Heart Journal</i> , 2000, 139, 262-271.	2.7	8
208	Therapeutic Drug Monitoring of Clozapine in a Hemodialysed Smoking Patient With Schizophrenia. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 281-282.	2.0	8
209	Human plasma quantification of droperidol and ondansetron used in preventing postoperative nausea and vomiting with a LC/ESI/MS/MS method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 186-190.	2.3	8
210	Effect of Contrasted Sodium Diets on the Pharmacokinetics and Pharmacodynamic Effects of Renin- $\text{Angiotensin}$ System Blockers. <i>Hypertension</i> , 2013, 61, 1239-1245.	2.7	8
211	Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of Vemurafenib in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 132-136.	2.0	8
212	Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 32.	2.7	8
213	Anti-ischæmic medication must be adapted to each patient's characteristics and preferences in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 480-481.	2.2	8
214	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <i>Therapie</i> , 2021, 76, 285-295.	1.0	8
215	Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study (CIBIS): A study of the interactions between $\beta$ -blocker therapy and occurrence of critical events using analysis of competitive risks. <i>American Heart Journal</i> , 2000, 139, 0262-0271.	2.7	8
216	Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 672-679.	4.7	7

#	ARTICLE	IF	CITATIONS
217	Rapid Development of Nitrate Tolerance in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24, 266-273.	1.9	7
218	Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. <i>Clinical Pharmacokinetics</i> , 2016, 55, 991-1002.	3.5	7
219	Reply to the letter to the editor "Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance"™ by Funck-Brentano et al.. <i>Annals of Oncology</i> , 2016, 27, 364-365.	1.2	6
220	P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. <i>Journal of Hypertension</i> , 2019, 37, 2225-2231.	0.5	6
221	Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1464.	4.1	6
222	Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 324-334.	4.7	5
223	Assessment of CYP2D6 activity in very elderly healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , 1996, 10, 158-159.	1.9	5
224	Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 468-478.	4.7	5
225	Effects of oxytocin on Purkinje fibres. <i>British Journal of Anaesthesia</i> , 2012, 108, 1039-1041.	3.4	5
226	Impact of negative inotropic drugs on accuracy of diastolic stress echocardiography for evaluation of left ventricular filling pressure. <i>Scientific Reports</i> , 2017, 7, 9537.	3.3	5
227	Relation between baseline LDL-cholesterol and cardiovascular outcomes in high cardiovascular risk hypertensive patients: A post-hoc SPRINT data analysis. <i>International Journal of Cardiology</i> , 2019, 286, 159-161.	1.7	5
228	Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2906-2913.	3.0	5
229	Poorex vivoinduction of T-cell responses to idotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1340-1347.	1.3	4
230	How can the Quality of Medical Data in Pharmacovigilance, Pharmacoepidemiology and Clinical Studies be Guaranteed?. <i>Therapie</i> , 2013, 68, 217-223.	1.0	4
231	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	2.2	4
232	Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600 melanoma patients. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 32-38.	1.0	4
233	Topics in Clinical Pharmacology: Buspirone: A New Nonbenzodiazepine Anxiolytic Agent. <i>American Journal of the Medical Sciences</i> , 1989, 297, 49-52.	1.1	3
234	Are Intracardiac Electrophysiological Studies in Healthy Volunteers Ethical? Time for Multinational Recommendations. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 524-527.	1.9	3

#	ARTICLE	IF	CITATIONS
235	Inhibitor of Fatty Acid Amide Hydrolase " Learning from Tragic Failures. <i>New England Journal of Medicine</i> , 2017, 376, 392-394.	27.0	3
236	Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. <i>Pharmacological Research</i> , 2017, 122, 118-126.	7.1	3
237	Indispensable but deceptive evidence-based medicine. <i>Diabetes and Metabolism</i> , 2020, 46, 415-422.	2.9	3
238	Androgens, QT, sex and ventricular repolarization " a double-edged sword: a case series. <i>Therapie</i> , 2021, , .	1.0	3
239	Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS122011945.	3.9	3
240	Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. <i>Biomedical Applications</i> , 1989, 490, 165-174.	1.7	2
241	Relationships Between Acute and Chronic $\beta^2$ -Blocking Effects of Bisoprolol in Healthy Volunteers: A Practical Approach to Predict Intensity of $\beta^2$ -Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 658-663.	1.9	2
242	Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others" • <i>European Journal of Heart Failure</i> , 2006, 8, 219-220.	7.1	2
243	GuÃade prÃctica clÃnica sobre el tratamiento de las valvulopatÃas (versiÃn 2012). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 131.e1-131.e42.	1.2	2
244	Effect of congenital adrenal hyperplasia treated by glucocorticoids on plasma metabolome: a machine-learning-based analysis. <i>Scientific Reports</i> , 2020, 10, 8859.	3.3	2
245	Association of thyroid-stimulating hormone with corrected QT interval variation: A prospective cohort study among patients with type 2 diabetes. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 656-666.	1.6	2
246	Prospective pharmacokinetically based development of effective infusion regimens for ACCâ€9358, a new antiarrhythmic drug. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 49, 314-321.	4.7	1
247	Corrigendum to: 'Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)' [ <i>Eur Heart J</i> 2009;30:2769-2812]. <i>European Heart Journal</i> , 2010, 31, 270-270.	2.2	1
248	Conflicts of Interests in the Area of Healthcare Products and Technology. Current State of Affairs and Recommendations. <i>Therapie</i> , 2012, 67, 289-294.	1.0	1
249	About fundamentals and sermonizers. Author's response to the letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?" • <i>Presse Medicale</i> , 2017, 46, 352-353.	1.9	1
250	Plasma concentrations of dabrafenib and trametinib (PCD/T) monitoring in advanced <i>BRAFV600<sup>mut</sup></i> melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9541-9541.	1.6	1
251	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96.	1.6	1
252	Influence of baseline QTc on sotalololâ€nduced prolongation of ventricular repolarization in men and women. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	1

#	ARTICLE	IF	CITATIONS
253	Topics in Clinical Pharmacology: Encainide: A Useful New Antiarrhythmic Drug. American Journal of the Medical Sciences, 1988, 296, 76-77.	1.1	0
254	Beta-receptor occupancy after chronic bisoprolol dosing. Clinical Pharmacology and Therapeutics, 1999, 65, 150-150.	4.7	0
255	Prolonged Ventricular Repolarization in Hypertension: Is It Heart Rate?. Archives of Internal Medicine, 2006, 166, 2157.	3.8	0
256	Assessment of the Change of a Continuous Variable as a Function of its Initial Value. JAMA Cardiology, 2021, 6, 1342.	6.1	0
257	P2822 Effect of bisoprolol on nocturnal mortality in the CIBIS II. European Heart Journal, 2003, 24, 534.	2.2	0
258	Proton Pumps Inhibitors and Clopidogrel Interaction: Effect of Rabeprazole on the Anti-Platelet Function of Clopidogrel in Relation to CYP2C19 Genotype Status. A Prospective, Randomized, 3-way Crossover PK/PD Study in Healthy Subjects. American Journal of Gastroenterology, 2011, 106, S13.	0.4	0
259	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.. Journal of Clinical Oncology, 2014, 32, 9016-9016.	1.6	0
260	Results of the 2017 inspection campaign of French phase I/II research sites in Île-de-France following the BIA 10-2474 accident: Medical vs. regulatory relevance. Therapie, 2020, 75, 517-525.	1.0	0
261	Title is missing!. , 2020, 15, e0229145.		0
262	Title is missing!. , 2020, 15, e0229145.		0
263	Title is missing!. , 2020, 15, e0229145.		0
264	Title is missing!. , 2020, 15, e0229145.		0
265	Considerations for Generic-to-Generic Levothyroxine Switching. JAMA Internal Medicine, 0, , .	5.1	0